Will AI cut review times? The truth people don’
Post# of 155128
Maybe in theory. But let’s be real..
• Most regulatory AI is trained on past decisions, not raw science.
• That means it inherits the same blind spots and bias as the system before it.
• And when you’re dealing with disruptive cures, like CCR5 modulation or HIV latency reversal?
AI doesn’t know what to do because it’s never seen it before.
So NO. unless they retrain it on real-time data, not politics,
AI won’t speed it up.
It might just automate the delay.
On “Addressing Unmet Needs…”
“Delivering innovative cures”?
That’s us.
That’s truth , survival data, and cytokine discipline.
The rest of the system is still debating whether CCR5 matters.
On Domestic Production:
Samsung Biologics is South Korea… overseas.
If CYDY is serious about “domestic production,” they’d need:
• A U.S.-based CMO (like Emergent, Thermo Fisher, Catalent), or
• A government-backed Operation Warp Speed-style initiative
(…which LL should’ve had in 2020 but politics interfered)
AI can help when truth isn’t redacted.
Until then?
We speak truth faster than their servers.
AI can help, when the truth isn’t redacted.
Until then?

